Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Pasquale Romeo"'
Autor:
Marco Favio Michele Vismara, Emma Colao, Fernanda Fabiani, Francesco Bombardiere, Oscar Tamburrini, Caterina Alessio, Francesco Manti, Gerolamo Pelaia, Pasquale Romeo, Rodolfo Iuliano, Nicola Perrotti
Publikováno v:
Respiratory Medicine Case Reports, Vol 16, Iss C, Pp 77-80 (2015)
Pulmonary alveolar microlithiasis is a disorder in which many tiny fragments (microliths) of calcium phosphate gradually accumulate in alveoli. Loss of function mutations in the gene SLC34A2 coding for the sodium phosphate co-transporter (NaPi-IIb) a
Externí odkaz:
https://doaj.org/article/3540632197364db1a4701cc4686b3d95
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 2 (2008)
Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for the treatment of severe allergic asthma. This drug inhibits allergic responses by binding to serum IgE, thus preventing their interactions with cellular IgE receptors. Omali
Externí odkaz:
https://doaj.org/article/71b0b36ee25b419684f9b8ee32b94c26
Autor:
Nicola Perrotti, Francesco Bombardiere, Gerolamo Pelaia, Rodolfo Iuliano, Fernanda Fabiani, Marco Favio Michele Vismara, Francesco Manti, Caterina Alessio, Emma Colao, Oscar Tamburrini, Pasquale Romeo
Publikováno v:
Respiratory Medicine Case Reports
Respiratory Medicine Case Reports, Vol 16, Iss C, Pp 77-80 (2015)
Respiratory Medicine Case Reports, Vol 16, Iss C, Pp 77-80 (2015)
Pulmonary alveolar microlithiasis is a disorder in which many tiny fragments (microliths) of calcium phosphate gradually accumulate in alveoli. Loss of function mutations in the gene SLC34A2 coding for the sodium phosphate co-transporter (NaPi-IIb) a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0830f9dc8a199cbb76e8abddfcf404e
http://europepmc.org/articles/PMC4681981
http://europepmc.org/articles/PMC4681981
Autor:
Maria Teresa Busceti, Alessandro Vatrella, Serafino A. Marsico, Luca Gallelli, Rosa Daniela Grembiale, Girolamo Pelaia, Rosario Maselli, Pasquale Romeo, Teresa Renda
Publikováno v:
Journal of Asthma and Allergy
Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for the treatment of severe allergic asthma. This drug inhibits allergic responses by binding to serum IgE, thus preventing interaction with cellular IgE receptors. Omalizumab i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::245c82f7190d71138cd0e47da4f720bc
https://doi.org/10.2147/jaa.s14520
https://doi.org/10.2147/jaa.s14520
Autor:
Mt Busceti, Pasquale Romeo, Teresa Renda, Rosario Maselli, A Proietto, Alessandro Vatrella, Sa Marsico, Rd Grembiale, Luca Gallelli, G. Pelaia
Publikováno v:
Europe PubMed Central
Omalizumab is a humanized monoclonal anti-IgE antibody approved in 2005 by the European Medicine Agency (EMA) for the treatment of severe persistent allergic asthma, which remains inadequately controlled despite optimal therapy with high doses of inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce013c1e0b718723983999b19d906fbe
http://europepmc.org/abstract/med/22122813
http://europepmc.org/abstract/med/22122813
